2021
DOI: 10.1016/j.pep.2020.105750
|View full text |Cite
|
Sign up to set email alerts
|

A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…According to WHO's report in 2017, more than 95% of new cases of CL occurred in Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, and Syria. [ 6 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…According to WHO's report in 2017, more than 95% of new cases of CL occurred in Afghanistan, Algeria, Brazil, Colombia, Iran, Iraq, and Syria. [ 6 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…The research results of Zhu and colleagues showed that the expression product of P. pastoris had better rapid performance and immune effects than the expression product of E. coli [ 38 ]. To date, P. pastoris has been successfully used to produce AMPs (such as TH2-3), enzyme preparations (such as xylanase) and vaccines (such as PpSP15) [ 39 41 ]. Therefore, this study chose P. pastoris as the production factory for LG.…”
Section: Resultsmentioning
confidence: 99%